The Efficacy, Side Effect, and Cost-effectiveness of Uperio for Heart Failure: A Literature Review A Literature Review
Article Sidebar
Main Article Content
Abstract
Heart failure (HF) is a clinical syndrome that results when the heart is unable to provide sufficient blood flow to meet metabolic requirements or accommodate a systemic venous return. HF is a costly condition that consumes 1–2% of the total healthcare budget. Recently, angiotensin receptor/neprilysin inhibitors (ARNIs; sacubitril/valsartan, Uperio®) showed a highly significant and clinically relevant reduction in mortality and heart failure hospitalizations, and improvement of quality of life when added to current standard drugs in patients with heart failure with reduced ejection fraction. (HFrEF). Sacubitril is an neprilysin inhibitor to slow down natriuretic peptide (NP) breakdown, effectively increasing their vasodilation effect. NP levels are elevated in patients with HF and other cardiac diseases for restoring normal circulatory conditions. As for valsartan, this is an angiotensin receptor blocker (ARB). It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II. Although Uperio has fewer side effects, more effectiveness it is considered a high-priced heart failure medication and needs further economic impact.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
© Journal of Asian Medical Students’ Association (JAMSA). Released under a Creative Commons license.
References
M. R. Cowie*, A. Mosterdft, D. A. Wood*, J. W. Deckers*, P. A. Poole-Wilson*, G. C. Sutton* and D. E. Grobbeef The epidemiology of heart failure European Heart Journal (1997) 18, 208-225
Clinton D. Kemp, John V. Conte The pathophysiology of heart failure,2012, 365-371
Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions N Engl J Med 1992; 327:685-691
Bertram Pitt, Robert Segal, Felipe A Martinez, Georg Meurers, Alan J Cowley, Ignatius Thomas, Prakash C Deedwania, Dawn E Ney, Duane B Snavely, Paul I Chang Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) 1997, 747-752,
J. Parameshwar, P. A. Poole-Wilson, The role of calcium antagonists in the treatment of chronic heart failure, European Heart Journal, Volume 14, Issue suppl_A, July 1993, Pages 38–44
HOSENPUD, J. D1 ; BENNETT, L. E1 ; KECK, B. M1 ; FIOL, B1 ; NOVICK, R. J The Journal of heart and lung transplantation. 1997, Vol 16, Num 7, pp 691-712
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89– 94.
Kerkela R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 2015; 4: e002423.
Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003; 100: 1426– 31.
Suga S, Itoh H, Komatsu Y, Ogawa Y, Hama N, Yoshimasa T et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells–evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993; 133: 3038– 41.
Federico C. Natriuretic peptide system and cardiovascular disease. Heart Views 2010; 11: 10– 5.
Sarzani R, Spannella F, Giulietti F, Balietti P, Cocci G, Bordicchia M. Cardiac natriuretic peptides, hypertension and cardiovascular risk. High Blood Press Cardiovasc Prev 2017; 24: 115– 26.
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34: 886– 93c.
Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005; 26: 901– 32.
Guo LJ, Alli AA, Eaton DC, Bao HF. ENaC is regulated by natriuretic peptide receptor-dependent cGMP signaling. Am J Physiol Renal Physiol 2013; 304: F930– 7.
Drewett JG, Fendly BM, Garbers DL, Lowe DG. Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J Biol Chem 1995; 270: 4668– 74.
Wei CM, Aarhus LL, Miller VM, Burnett JC Jr. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993; 264: H71– 3.
Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994; 78: 1428– 35.
Imura H, Nakao K, Itoh H. The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. Front Neuroendocrinol 1992; 13: 217– 49.
Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243: 183– 7.
Information on EC 3.4.24.11—neprilysin. BRENDA: The Comprehensive Enzyme Information System.
Ronco P, Pollard H, Galceran M, Delauche M, Schwartz JC, Verroust P. Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. Lab Invest 1988; 58: 210– 7.
Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87– 146.
Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril)–A possible new treatment for hypertension and heart failure. Basic Clin Pharmacol Toxicol 2016; 118: 14– 22.
Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401– 14.
Han Y, Ayalasomayajula S, Pan W, Yang F, Yuan Y, Langenickel T et al. Pharmacokinetics, safety and tolerability of Sacubitril/Valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet 2017; 42: 109– 16.
Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 2013; 19: 1085– 94.
Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol 2016; 221: 60– 74.
Geng Q, Yan R, Wang Z, Hou F: Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials. Cardiology 2020;145:589-598.
Ye L, Wang J, Chen Q, Yang X. LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials). Oncotarget. 2017 Nov 14;8(64):107991-108005.
Zhao Y, Yu H, Zhao X, Ma R, Li N, Yu J. The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(5):447-457.
Bouabdallaoui, N., Claggett, B., Zile, M.R., McMurray, J.J.V., O'Meara, E., Packer, M., Prescott, M.F., Swedberg, K., Solomon, S.D., Rouleau, J.L. and (2018), Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail, 20: 1701-1709.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993– 1004.
McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 2015; 36: 434– 9.
Iborra-Egea, O., Gálvez-Montón, C., Roura, S. et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. npj Syst Biol Appl 3, 12 (2017)
Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Therapeutic Advances in Endocrinology and Metabolism. 2020;11.
Zile M, O'Meara E, Claggett B, et al. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019 Feb, 73 (7) 795–806.
Senni, M., McMurray, J.J.V., Wachter, R., McIntyre, H.F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M.B., Gogia, H., Martinez-Selles, M., Fischer, S., Zilahi, Z., Cosmi, F., Gelev, V., Galve, E., Gómez-Doblas, J.J., Nociar, J., Radomska, M., Sokolova, B., Volterrani, M., Sarkar, A., Reimund, B., Chen, F. and Charney, A. (2016), Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail, 18: 1193-1202.
Lægemiddel-Styrelsen. Medicinpriser.